vimarsana.com

Latest Breaking News On - Proof of concept trial using dual energy computed - Page 1 : vimarsana.com

Latest Updates of Viva s Portfolio Companies

/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.

United statesAl iskandariyahSan diegoSouth san franciscoViva bioinnovatorPrnewswire triumvira immunologicsDetlev biniszkiewiczJohn mummDeka biosciencesHuya bioTriumvira immunologicsGenhouse bioArthrosi therapeutics incStrategic research collaborationTriumvira immunologics incBioshanghai biopharmaceutical industry investment forum

Sustained Serum Urate Reduction for Gout Patients Observed with AR882

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

San diegoUnited statesRobertt keenanEnergy computer tomographyAmerican college of rheumatology convergenceTrial using dual energy computed tomographyAmerican college of rheumatologyAmerican collegeDual energy computer tomographyArthrosi therapeuticsChronic gouty arthritisSubcutaneous tophiProof of concept trial using dual energy computedRheumatology convergence

Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023

/PRNewswire/ Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for gout that dissolve uric acid crystals and prevent.

San diegoUnited statesAlex loboLitain yehShunqi yanEuropean alliance of associationsTrial using dual energy computed tomographyArthrosi therapeutics incEnergy computed tomographyAmerican college of rheumatologyStern investor relations incRobert keenanChief medical officerDual energy computed tomographyChief executive officer litain yehChronic gouty arthritis

vimarsana © 2020. All Rights Reserved.